Cancer Drugs Have The Worst Phase III Track Record, BIO Study Shows

New data indicating that only one-third of oncologic agents succeed in Phase III, coupled with tougher regulatory hurdles ahead, could give big pharma and investors pause before committing resources in the therapeutic category.